Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.36 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303440 | 0.83 | ROCK1 (0.50) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL8299998 | 0.78 | ROCK1 (0.46) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL7567350 | 0.77 | ROCK1 (0.44) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL22320228 | 0.77 | GPR3 (0.40) | ROCK1MAPTKDM4E | |
| SCHEMBL5250330 | 0.76 | ROCK1 (0.43) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL8295552 | 0.72 | ROCK1 (0.56) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL12954833 | 0.69 | ROCK1 (0.53) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL2824862 | 0.69 | ROCK1 (0.53) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL2953458 | 0.69 | ROCK1 (0.49) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL1254005 | 0.69 | ROCK1 (0.49) | ROCK1CYP2A6NPSR1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629138-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3692029-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | PRF1, CASP1, FPR1 | ROCK1 3723/4885CYP2A6 622/4885NPSR1 888/4885 |
| US-11629138-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | ROCK1 3723/4885CYP2A6 622/4885NPSR1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.